93% of patients with HMR had a reduction in whole blood mutCALR VAF, as did 88% of those without HMR mutations. A reduction in mutCALR-positive hematopoietic stem and progenitor cells (HSPCs) was also ...
PF1007 PS2082 The Phase 2 EPCORE DLBCL-3 study (abstract PS2082 ) evaluated the efficacy and safety of fixed-duration epcoritamab monotherapy in newly diagnosed CD20+ large B-cell lymphoma (LBCL) ...
Sexual harassment remains a persistent feature of media workplaces worldwide, with one in three people surveyed experiencing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results